BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 95.85 USD -1.47% Market Closed
Market Cap: 23B USD

BioNTech SE
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

BioNTech SE
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
BioNTech SE
NASDAQ:BNTX
Gross Profit
€2.3B
CAGR 3-Years
-47%
CAGR 5-Years
91%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Gross Profit
€429.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Gross Profit
€147.3m
CAGR 3-Years
21%
CAGR 5-Years
1%
CAGR 10-Years
-4%
Heidelberg Pharma AG
XETRA:HPHA
Gross Profit
€5.1m
CAGR 3-Years
N/A
CAGR 5-Years
7%
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Gross Profit
€14.1m
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
8%
No Stocks Found

BioNTech SE
Glance View

BioNTech SE, founded in 2008 by the visionary duo Ugur Sahin and Özlem Türeci, has gradually emerged as a shining beacon in the world of biotechnology. Situated in Mainz, Germany, BioNTech carved its niche by focusing on the development of personalized therapies for cancer and other serious diseases. The company’s core competence lies in utilizing messenger RNA (mRNA) technology, which allows it to instruct the body to produce proteins that can stimulate an immune response. This technology became a game changer, not only in the cancer arena but also expanded its reach into infectious diseases, showcasing a broader horizon of possibilities. BioNTech’s ability to leverage its research expertise in mRNA placed it at the forefront of scientific innovation, demonstrating breathtaking adaptability and ingenuity. The company's business model thrives on strategic partnerships and collaborations, which bolster both its scientific output and financial standing. One of its most celebrated partnerships is with Pfizer, a collaboration that led to the development of the groundbreaking COVID-19 vaccine, Comirnaty. This collaboration thrust BioNTech onto the global stage, underscoring its capacity to swiftly respond to urgent health crises while generating substantial revenue. The success and distribution of the vaccine not only provided a significant boost to BioNTech’s financials but also validated its platform as powerful and versatile. By continually investing in research and development, both independently and through alliances, BioNTech aims to solidify its position as a leader in the evolving biotech landscape, paving the way for future therapies that could redefine medical treatments.

BNTX Intrinsic Value
HIDDEN
Show

See Also

What is BioNTech SE's Gross Profit?
Gross Profit
2.3B EUR

Based on the financial report for Dec 31, 2024, BioNTech SE's Gross Profit amounts to 2.3B EUR.

What is BioNTech SE's Gross Profit growth rate?
Gross Profit CAGR 5Y
91%

Over the last year, the Gross Profit growth was -27%. The average annual Gross Profit growth rates for BioNTech SE have been -47% over the past three years , 91% over the past five years .

Back to Top